カテゴリー： P&S Market Research, 世界, 医療/バイオ

使い捨てバイオリアクターのグローバル市場：製品種類別、種類別、細胞種類別、分子種類別、用途別、使用別、エンドユーザー別

◆英語タイトル：Single-Use Bioreactors Market Size and Share Analysis by Product Type (Systems, Media Bags, Assemblies), Type (Wave-Induced, Stirred-Tank), Cell Type (Mammalian Cells, Yeast Cells, Bacterial Cells), Molecule Type (Monoclonal Antibodies, Gene-Modified Cells, Vaccines, Stem Cells), Application (Research & Development, Process Development, Bioproduction), Usage Type (Lab-Scale Production, Pilot-Scale Production, Large-Scale Production), End User (CROs & CMOs, Pharmaceutical & Biotechnology Companies, Academic & Research Institutions) - Global Industry Demand Forecast to 2030

P&S Market Researchが発行した調査報告書（PS23SEP040）◆商品コード：PS23SEP040
◆発行会社（リサーチ会社）：P&S Market Research
◆発行日：2023年6月
◆ページ数：210
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：バイオ
◆販売価格オプション（消費税別）
Single UserUSD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
5 UserUSD6,400 ⇒換算￥972,800見積依頼/購入/質問フォーム
Enterprise UserUSD8,400 ⇒換算￥1,276,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

使い捨てバイオリアクター市場は、今後数年間で年平均成長率18.8%で成長し、2030年には135億9,590万米ドルの規模に達する見込みです。この産業の成長の原動力は、感染症や慢性疾患の有病率の増加です。
世界的に感染症が大幅に増加しています。COVID-19の大流行により、ライフサイエンスおよびバイオ医薬品企業は、ワクチンを迅速かつ大規模に製造するための先端技術を急速に導入するようになりました。このため、柔軟性とモジュール性に優れ、投資が不足している新興国での現地製造が可能な使い捨てシステムの需要が高まっています。これらのシステムは主にウイルスワクチンの製造に利用されています。ヒトにおけるCOVID-19ウイルスの挙動をよりよく理解するために、バイオリアクターを使用して適切な宿主細胞を培養しているメーカーもあります。さらに、市場ポジションを強化するために、いくつかの企業が共同研究に参入しています。

新興企業や中小企業では、従来のバイオ製造施設の設置に高いコストがかかるため、バイオリアクターの利用が増えています。これらの企業は、年間生産バッチ数が少なく、ステンレス製設備が高価であると感じています。その結果、設備投資が少なくて済み、バリデーション、滅菌、洗浄、交換工程が不要な使い捨てシステムの採用が進んでいます。

システム・カテゴリーが市場を支配し、2022年の売上シェアは55%です。これは、高い製品収率を必要とするバイオ医薬品製造施設で広く使用されているためです。これらのシステムはコスト効率が高く、汎用性があり、大規模生産が可能で、抗体、ホルモン、ワクチン、酵素などのバイオ医薬品の需要増に対応しています。

北米が使い捨てバイオリアクター市場を支配しているのは、慢性疾患の有病率の高さ、トップ企業の存在、高度な医療施設、技術の進歩、強力な研究開発イニシアティブなどの要因によるものです。北米内では、革新的技術の採用、疾病予防に関する国民の意識、政府の支援、高度な医療インフラが原動力となり、米国が重要な役割を果たしています。感染症の増加により、2022年にはワクチンカテゴリーが最大の収益シェアを獲得しました。予防と治療を目的としたワクチンの大量生産に対する需要が増加。COVID-19パンデミックはワクチン製造をさらに加速させ、使い捨てバイオリアクターの採用につながりました。

ラボスケール生産が業界をリードしています。これは、バイオ医薬品業界がさまざまな前臨床および臨床研究目的でバイオリアクターの頻繁な使用を必要としているためです。さらに、使い捨て技術の受け入れと進歩の増加は、将来的に業界の拡大を大きく後押しするでしょう。医療業界における研究開発活動の増加により、使い捨てバイオリアクターの需要は今後も増加し続けるでしょう。

第1章．調査範囲
第2章．調査方法
第3章．エグゼクティブサマリー
第4章．産業専門家の意見/KOL
第5章．市場指標
第6章．産業動向
第7章．世界市場
第8章．北米市場
第9章．ヨーロッパ市場
第10章．アジア太平洋市場
第11章．中南米市場
第12章．中東・アフリカ市場
第13章．アメリカ市場
第14章．カナダ市場
第15章．ドイツ市場
第16章．フランス市場
第17章．イギリス市場
第18章．イタリア市場
第19章．スペイン市場
第20章．日本市場
第21章．中国市場
第22章．インド市場
第23章．オーストラリア市場
第24章．韓国市場
第25章．ブラジル市場
第26章．メキシコ市場
第27章．サウジアラビア市場
第28章．南アフリカ市場
第29章．UAE市場
第30章．競争状況
第31章．企業情報
第32章．付録

❖ レポートの目次 ❖

Chapter 1. Research Scope

1.1. Research Objectives

1.2. Market Definition

1.3. Analysis Period

1.4. Market Size Breakdown by Segments

1.4.1. Market size breakdown, by product type

1.4.2. Market size breakdown, by type

1.4.3. Market size breakdown, by cell type

1.4.4. Market size breakdown, by molecule type

1.4.5. Market size breakdown, by application

1.4.6. Market size breakdown, by usage type

1.4.7. Market size breakdown, by end user

1.4.8. Market size breakdown, by region

1.4.9. Market size breakdown, by country

1.5. Market Data Reporting Unit

1.5.1. Value

1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.1.1. Paid

2.1.2. Unpaid

2.1.3. P&S Intelligence database

2.2. Primary Research

2.3. Market Size Estimation

2.4. Data Triangulation

2.5. Currency Conversion Rates

2.6. Assumptions for the Study

2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

6.1. Market Dynamics

6.1.1. Trends

6.1.2. Drivers

6.1.3. Restraints/challenges

6.1.4. Impact analysis of drivers/restraints

6.2. Impact of COVID-19

6.3. Porter’s Five Forces Analysis

6.3.1. Bargaining power of buyers

6.3.2. Bargaining power of suppliers

6.3.3. Threat of new entrants

6.3.4. Intensity of rivalry

6.3.5. Threat of substitutes

Chapter 7. Global Market

7.1. Overview

7.2. Market Revenue, by Product type (2017–2030)

7.3. Market Revenue, by Type (2017–2030)

7.4. Market Revenue, by Cell type (2017–2030)

7.5. Market Revenue, by Molecule type (2017–2030)

7.6. Market Revenue, by Application (2017–2030)

7.7. Market Revenue, by Usage type (2017–2030)

7.8. Market Revenue, by End user (2017–2030)

7.9. Market Revenue, by Region (2017–2030)

Chapter 8. North America Market

8.1. Overview

8.2. Market Revenue, by Product type (2017–2030)

8.3. Market Revenue, by Type (2017–2030)

8.4. Market Revenue, by Cell type (2017–2030)

8.5. Market Revenue, by Molecule type (2017–2030)

8.6. Market Revenue, by Application (2017–2030)

8.7. Market Revenue, by Usage type (2017–2030)

8.8. Market Revenue, by End user (2017–2030)

8.9. Market Revenue, by Country (2017–2030)

Chapter 9. Europe Market

9.1. Overview

9.2. Market Revenue, by Product type (2017–2030)

9.3. Market Revenue, by Type (2017–2030)

9.4. Market Revenue, by Cell type (2017–2030)

9.5. Market Revenue, by Molecule type (2017–2030)

9.6. Market Revenue, by Application (2017–2030)

9.7. Market Revenue, by Usage type (2017–2030)

9.8. Market Revenue, by End user (2017–2030)

9.9. Market Revenue, by Country (2017–2030)

Chapter 10. APAC Market

10.1. Overview

10.2. Market Revenue, by Product type (2017–2030)

10.3. Market Revenue, by Type (2017–2030)

10.4. Market Revenue, by Cell type (2017–2030)

10.5. Market Revenue, by Molecule type (2017–2030)

10.6. Market Revenue, by Application (2017–2030)

10.7. Market Revenue, by Usage type (2017–2030)

10.8. Market Revenue, by End user (2017–2030)

10.9. Market Revenue, by Country (2017–2030)

Chapter 11. LATAM Market

11.1. Overview

11.2. Market Revenue, by Product type (2017–2030)

11.3. Market Revenue, by Type (2017–2030)

11.4. Market Revenue, by Cell type (2017–2030)

11.5. Market Revenue, by Molecule type (2017–2030)

11.6. Market Revenue, by Application (2017–2030)

11.7. Market Revenue, by Usage type (2017–2030)

11.8. Market Revenue, by End user (2017–2030)

11.9. Market Revenue, by Country (2017–2030)

Chapter 12. MEA Market

12.1. Overview

12.2. Market Revenue, by Product type (2017–2030)

12.3. Market Revenue, by Type (2017–2030)

12.4. Market Revenue, by Cell type (2017–2030)

12.5. Market Revenue, by Molecule type (2017–2030)

12.6. Market Revenue, by Application (2017–2030)

12.7. Market Revenue, by Usage type (2017–2030)

12.8. Market Revenue, by End user (2017–2030)

12.9. Market Revenue, by Country (2017–2030)

Chapter 13. U.S. Market

13.1. Overview

13.2. Market Revenue, by Product type (2017–2030)

13.3. Market Revenue, by Type (2017–2030)

13.4. Market Revenue, by Cell type (2017–2030)

13.5. Market Revenue, by Molecule type (2017–2030)

13.6. Market Revenue, by Application (2017–2030)

13.7. Market Revenue, by Usage type (2017–2030)

13.8. Market Revenue, by End user (2017–2030)

Chapter 14. Canada Market

14.1. Overview

14.2. Market Revenue, by Product type (2017–2030)

14.3. Market Revenue, by Type (2017–2030)

14.4. Market Revenue, by Cell type (2017–2030)

14.5. Market Revenue, by Molecule type (2017–2030)

14.6. Market Revenue, by Application (2017–2030)

14.7. Market Revenue, by Usage type (2017–2030)

14.8. Market Revenue, by End user (2017–2030)

Chapter 15. Germany Market

15.1. Overview

15.2. Market Revenue, by Product type (2017–2030)

15.3. Market Revenue, by Type (2017–2030)

15.4. Market Revenue, by Cell type (2017–2030)

15.5. Market Revenue, by Molecule type (2017–2030)

15.6. Market Revenue, by Application (2017–2030)

15.7. Market Revenue, by Usage type (2017–2030)

15.8. Market Revenue, by End user (2017–2030)

Chapter 16. France Market

16.1. Overview

16.2. Market Revenue, by Product type (2017–2030)

16.3. Market Revenue, by Type (2017–2030)

16.4. Market Revenue, by Cell type (2017–2030)

16.5. Market Revenue, by Molecule type (2017–2030)

16.6. Market Revenue, by Application (2017–2030)

16.7. Market Revenue, by Usage type (2017–2030)

16.8. Market Revenue, by End user (2017–2030)

Chapter 17. U.K. Market

17.1. Overview

17.2. Market Revenue, by Product type (2017–2030)

17.3. Market Revenue, by Type (2017–2030)

17.4. Market Revenue, by Cell type (2017–2030)

17.5. Market Revenue, by Molecule type (2017–2030)

17.6. Market Revenue, by Application (2017–2030)

17.7. Market Revenue, by Usage type (2017–2030)

17.8. Market Revenue, by End user (2017–2030)

Chapter 18. Italy Market

18.1. Overview

18.2. Market Revenue, by Product type (2017–2030)

18.3. Market Revenue, by Type (2017–2030)

18.4. Market Revenue, by Cell type (2017–2030)

18.5. Market Revenue, by Molecule type (2017–2030)

18.6. Market Revenue, by Application (2017–2030)

18.7. Market Revenue, by Usage type (2017–2030)

18.8. Market Revenue, by End user (2017–2030)

Chapter 19. Spain Market

19.1. Overview

19.2. Market Revenue, by Product type (2017–2030)

19.3. Market Revenue, by Type (2017–2030)

19.4. Market Revenue, by Cell type (2017–2030)

19.5. Market Revenue, by Molecule type (2017–2030)

19.6. Market Revenue, by Application (2017–2030)

19.7. Market Revenue, by Usage type (2017–2030)

19.8. Market Revenue, by End user (2017–2030)

Chapter 20. Japan Market

20.1. Overview

20.2. Market Revenue, by Product type (2017–2030)

20.3. Market Revenue, by Type (2017–2030)

20.4. Market Revenue, by Cell type (2017–2030)

20.5. Market Revenue, by Molecule type (2017–2030)

20.6. Market Revenue, by Application (2017–2030)

20.7. Market Revenue, by Usage type (2017–2030)

20.8. Market Revenue, by End user (2017–2030)

Chapter 21. China Market

21.1. Overview

21.2. Market Revenue, by Product type (2017–2030)

21.3. Market Revenue, by Type (2017–2030)

21.4. Market Revenue, by Cell type (2017–2030)

21.5. Market Revenue, by Molecule type (2017–2030)

21.6. Market Revenue, by Application (2017–2030)

21.7. Market Revenue, by Usage type (2017–2030)

21.8. Market Revenue, by End user (2017–2030)

Chapter 22. India Market

22.1. Overview

22.2. Market Revenue, by Product type (2017–2030)

22.3. Market Revenue, by Type (2017–2030)

22.4. Market Revenue, by Cell type (2017–2030)

22.5. Market Revenue, by Molecule type (2017–2030)

22.6. Market Revenue, by Application (2017–2030)

22.7. Market Revenue, by Usage type (2017–2030)

22.8. Market Revenue, by End user (2017–2030)

Chapter 23. Australia Market

23.1. Overview

23.2. Market Revenue, by Product type (2017–2030)

23.3. Market Revenue, by Type (2017–2030)

23.4. Market Revenue, by Cell type (2017–2030)

23.5. Market Revenue, by Molecule type (2017–2030)

23.6. Market Revenue, by Application (2017–2030)

23.7. Market Revenue, by Usage type (2017–2030)

23.8. Market Revenue, by End user (2017–2030)

Chapter 24. South Korea Market

24.1. Overview

24.2. Market Revenue, by Product type (2017–2030)

24.3. Market Revenue, by Type (2017–2030)

24.4. Market Revenue, by Cell type (2017–2030)

24.5. Market Revenue, by Molecule type (2017–2030)

24.6. Market Revenue, by Application (2017–2030)

24.7. Market Revenue, by Usage type (2017–2030)

24.8. Market Revenue, by End user (2017–2030)

Chapter 25. Brazil Market

25.1. Overview

25.2. Market Revenue, by Product type (2017–2030)

25.3. Market Revenue, by Type (2017–2030)

25.4. Market Revenue, by Cell type (2017–2030)

25.5. Market Revenue, by Molecule type (2017–2030)

25.6. Market Revenue, by Application (2017–2030)

25.7. Market Revenue, by Usage type (2017–2030)

25.8. Market Revenue, by End user (2017–2030)

Chapter 26. Mexico Market

26.1. Overview

26.2. Market Revenue, by Product type (2017–2030)

26.3. Market Revenue, by Type (2017–2030)

26.4. Market Revenue, by Cell type (2017–2030)

26.5. Market Revenue, by Molecule type (2017–2030)

26.6. Market Revenue, by Application (2017–2030)

26.7. Market Revenue, by Usage type (2017–2030)

26.8. Market Revenue, by End user (2017–2030)

Chapter 27. Saudi Arabia Market

27.1. Overview

27.2. Market Revenue, by Product type (2017–2030)

27.3. Market Revenue, by Type (2017–2030)

27.4. Market Revenue, by Cell type (2017–2030)

27.5. Market Revenue, by Molecule type (2017–2030)

27.6. Market Revenue, by Application (2017–2030)

27.7. Market Revenue, by Usage type (2017–2030)

27.8. Market Revenue, by End user (2017–2030)

Chapter 28. South Africa Market

28.1. Overview

28.2. Market Revenue, by Product type (2017–2030)

28.3. Market Revenue, by Type (2017–2030)

28.4. Market Revenue, by Cell type (2017–2030)

28.5. Market Revenue, by Molecule type (2017–2030)

28.6. Market Revenue, by Application (2017–2030)

28.7. Market Revenue, by Usage type (2017–2030)

28.8. Market Revenue, by End user (2017–2030)

Chapter 29. U.A.E. Market

29.1. Overview

29.2. Market Revenue, by Product type (2017–2030)

29.3. Market Revenue, by Type (2017–2030)

29.4. Market Revenue, by Cell type (2017–2030)

29.5. Market Revenue, by Molecule type (2017–2030)

29.6. Market Revenue, by Application (2017–2030)

29.7. Market Revenue, by Usage type (2017–2030)

29.8. Market Revenue, by End user (2017–2030)

Chapter 30. Competitive Landscape

30.1. List of Market Players and their Offerings

30.2. Competitive Benchmarking of Key Players

30.3. Product Benchmarking of Key Players

30.4. Recent Strategic Developments

Chapter 31. Company Profiles

31.1. Sartorius AG

31.1.1. Business overview

31.1.2. Product and service offerings

31.1.3. Key financial summary

31.2. Thermo Fisher Scientific Inc

31.2.1. Business overview

31.2.2. Product and service offerings

31.2.3. Key financial summary

31.3. Getinge AB

31.3.1. Business overview

31.3.2. Product and service offerings

31.3.3. Key financial summary

31.4. Merck KGaA

31.4.1. Business overview

31.4.2. Product and service offerings

31.4.3. Key financial summary

31.5. Eppendorf SE

31.5.1. Business overview

31.5.2. Product and service offerings

31.5.3. Key financial summary

31.6. PBS Biotech, Inc

31.6.1. Business overview

31.6.2. Product and service offerings

31.7. Distek, Inc

31.7.1. Business overview

31.7.2. Product and service offerings

31.8. ABEC Inc.

31.8.1. Business overview

31.8.2. Product and service offerings

31.9. G&G Technologies Inc

31.9.1. Business overview

31.9.2. Product and service offerings

31.10. Solida Biotech GmBH

31.10.1. Business overview

31.10.2. Product and service offerings

31.11. Surplus Solutions LLC

31.11.1. Business overview

31.11.2. Product and service offerings

31.12. Esco Micro Pte Ltd

31.12.1. Business overview

31.12.2. Product and service offerings

31.13. Celltainer Biotech BV

31.13.1. Business overview

31.13.2. Product and service offerings

31.14. Stobbe Pharma GmbH

31.14.1. Business overview

31.14.2. Product and service offerings

31.15. SATAKE MultiMix Corporation

31.15.1. Business overview

31.15.2. Product and service offerings

Chapter 32. Appendix

32.1. Abbreviations

32.2. Sources and References

32.3. Related Reports



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 使い捨てバイオリアクターのグローバル市場：製品種類別、種類別、細胞種類別、分子種類別、用途別、使用別、エンドユーザー別(Single-Use Bioreactors Market Size and Share Analysis by Product Type (Systems, Media Bags, Assemblies), Type (Wave-Induced, Stirred-Tank), Cell Type (Mammalian Cells, Yeast Cells, Bacterial Cells), Molecule Type (Monoclonal Antibodies, Gene-Modified Cells, Vaccines, Stem Cells), Application (Research & Development, Process Development, Bioproduction), Usage Type (Lab-Scale Production, Pilot-Scale Production, Large-Scale Production), End User (CROs & CMOs, Pharmaceutical & Biotechnology Companies, Academic & Research Institutions) - Global Industry Demand Forecast to 2030)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 超音波プローブカバーのグローバル市場：種類別、製品種類別、用途別、エンドユーザー別
  • PTAバルーンカテーテルのグローバル市場：素材種類別、用途別、エンドユーザー別、製品種類別
  • 医薬品無菌試験のグローバル市場：種類別、製品種類別、試験種類別、用途別、エンドユーザー別
  • 分子品質管理のグローバル市場：製品種類別、分析対象物種類別、用途別、エンドユーザー別
  • 吻合器のグローバル市場：種類別、製品種類別、用途別、エンドユーザー別

    • ◆H&Iグローバルリサーチのお客様（例）◆